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The cardiorenal safety database from the Celecoxib Long-term
Arthritis Safety Study (CLASS) was analyzed to examine
whether supratherapeutic doses of celecoxib are associated
with decreased renal function and blood pressure (BP) effects
compared with standard doses of diclofenac and ibuprofen in
osteoarthritis (OA) and rheumatoid arthritis (RA) patients.
In total, 8059 patients were enrolled; 7968 received at least
one dose of study drug (RA: N¼ 2183; OA: N¼ 5785). Patients
received celecoxib, 400 mg twice a day (b.i.d.). (N¼ 3987);
ibuprofen, 800 mg three times a day. (N¼ 1985); or diclofenac,
75 mg b.i.d. (N¼ 1996). Effects measured included: investigator-
reported hypertension, edema or congestive heart failure,
clinically important BP elevations, incidence of patients starting
new antihypertensive medication, and increases in serum
creatinine or reductions in creatinine clearance. Celecoxib was
associated with a similar incidence of hypertension or edema to
diclofenac but significantly lower than ibuprofen. The celecoxib
group had significantly fewer initiations of antihypertensives
versus ibuprofen. Systolic BP increases of 420 mmHg and
above 140 mmHg occurred significantly less often with
celecoxib compared with ibuprofen or diclofenac. Changes in
serum creatinine or estimated creatinine clearance occurred in
a similar percentage of patients taking celecoxib or ibuprofen;
modest differences were evident against diclofenac. In patients
with mild prerenal azotemia, significantly fewer patients taking
celecoxib exhibited clinically important reductions in renal
function (3.7%), compared with diclofenac (7.3%; Po0.05)
and ibuprofen (7.3%; Po0.05). A supratherapeutic dose of
celecoxib was associated with an improved cardiorenal safety
profile compared with standard doses of either ibuprofen or
diclofenac.
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Nonselective nonsteroidal anti-inflammatory drugs
(NSAIDs) are commonly used to manage the pain
and inflammation associated with arthritis. However, these
agents inhibit both isoenzymes of cyclooxygenase (COX):
COX-1 and COX-2.1 Therefore, the use of nonselective
NSAIDs can result in a spectrum of mild-to-severe and
occasionally life-threatening mechanism-based adverse
events, particularly within the gastrointestinal tract, effects
on platelets, and the cardiorenal axis, which may limit their
therapeutic benefit.2–6 Celecoxib was the first of the COX-2
selective inhibitors (COXIBs) to be developed. At full
therapeutic doses, celecoxib possesses comparable analgesic
and anti-inflammatory efficacy to nonselective NSAIDs
in the treatment of rheumatoid arthritis (RA) and osteo-
arthritis (OA), although sparing COX-1 activity, thereby
avoiding many of the gastrointestinal- and platelet-related
adverse events.7–11
Nonselective inhibition of COX-1 and COX-2 attenuates
the prostaglandin-mediated mechanisms responsible for
modulating renal function, including renal vascular tone
and electrolyte and water excretion, particularly during renal
stress, as manifested by reduced renal perfusion.12,13 The
most common side effect is edema, which is followed by, and
frequently linked with, destabilization of blood pressure (BP)
control in treated hypertensive individuals. Retention of salt
and water is also linked to the blunting of clinical response to
diuretic treatment and may subsequently induce congestive
heart failure in susceptible individuals. In the setting of
reduced renal perfusion and, hence, dependence of renal
perfusion upon the compensatory production of prostaglan-
din synthesis, the use of a nonselective NSAID may result in
acute, hemodynamically mediated deterioration in renal
function. This is fully reversible following discontinuation
of the offending drug. Other renal syndromes are rare to very
rare. They include other electrolyte complications, such as
hyperkalemia, hyponatremia, nephrotic syndrome with
interstitial nephritis, and papillary necrosis. The mechanisms
of the induction of these rare events via inhibition of arachi-
donic acid processing by COX enzymes are reviewed in detail
elsewhere.14,15 It is remarkable to note that, following exposure
to several days’ treatment with nonselective NSAIDs,
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approximately one in five subjects will manifest a renal
function abnormality.16
COX-1 is expressed abundantly in the kidney. In the early
development of celecoxib, it was assumed that COX-2 was
not constitutively expressed in the healthy human kidney as
was the case in most other tissues with the exception of the
brain and the female reproductive system. However,
subsequent studies have demonstrated that the COX-2
isoenzyme is indeed constitutively expressed in discrete areas
of the adult mammalian kidney.17 For example, expression of
COX-2 in the macula densa suggests a role in the production
of prostaglandins regulating the release of renin. COX-2
expressed in the cortical thick ascending limb and medullary
interstitial cells may be involved in the regulation of
medullary blood flow. In the medulla, COX-2 expression
decreases with salt depletion and increases with a high-salt
diet and with dehydration.18,19 Thus, as information
accumulated, it became increasingly clear that COX-2 may
serve an important role in the regulation of renal hemo-
dynamic and/or renal excretory function under physiologic
or pathophysiologic conditions.20,21
Typically, the use of a selective COX-2 inhibitor in
otherwise healthy individuals is associated with mild edema,
hypertension, and modest sodium retention for the first 1 or
2 days of therapy followed by a return to baseline excretion
levels and elimination of retained salt and water.
As the kidney and vasculature are capable of expressing
both COX-1 and COX-2, it may be hypothesized that a
selective COX-2 inhibitor such as celecoxib may have
decreased renal adverse effects relative to nonselective
inhibitors. The Celecoxib Long-term Arthritis Safety Study
(CLASS) was undertaken to compare the long-term upper
gastrointestinal safety of celecoxib 400 mg twice a day (b.i.d.),
two to four times the full therapeutic doses for RA and OA,
respectively, with normal full therapeutic doses of diclofenac
(75 mg b.i.d.) and ibuprofen (800 mg three times a day). A
large cardiorenal safety database was accumulated in the
CLASS trial, which was determined to be useful for studying
cardiorenal-related adverse effects associated with nonselec-
tive NSAIDs and celecoxib. A separate publication has
detailed the cardiovascular thrombotic complications
observed during the CLASS trial.22
RESULTS
Patient disposition is outlined in Figure 1. A total of 8059
patients were randomized, of whom 7968 received at
least one dose of study drug, and were therefore included
in the intent-to-treat (ITT) population (RA: N¼ 2183;
Figure 1 | Patient disposition in CLASS. Of the 7968 patients randomized and took one dose of study medication (ITT cohort), 3409 patients
(43%) completed the study. The most common reason for withdrawal from the trial was for an adverse event, followed by lack of efficacy
and noncompliance with the protocol. CLASS¼Celecoxib Long-term Arthritis Safety Study; ITT¼ intent-to-treat.
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OA: N¼ 5785). In the ITT population, 3987 patients received
celecoxib and 3981 were treated with either ibuprofen or
diclofenac.
Baseline demographics, exposure to treatment, mean BP
levels, and renal function are shown in Table 1. Mean patient
age was 60 years in each treatment group, most (69–71%)
patients were female and mean BP was 133/80 mmHg. As
determined by medical history, slightly less than 40% of
patients in each treatment group had pre-existing hyper-
tension. Overall BP levels and renal function were normal at
baseline and comparable between treatment groups.
A summary of antihypertensive and diuretic medication
use at baseline is summarized in Table 2. Over 40% of the
patients in each treatment group were receiving one or more
of these agents, with nearly 20% receiving diuretics. Overall,
the frequency and distribution of use of these drugs were
similar across the treatment groups.
Blood pressure
Celecoxib was associated with an incidence of hypertension
(both new-onset and aggravated) that was comparable to
standard doses of diclofenac and significantly lower than
standard doses of ibuprofen (Po0.05) (Table 3). In patients
taking ibuprofen, the increased incidence of hypertension
versus celecoxib was accompanied by a corresponding trend
towards a mean increase in systolic BP (P¼ 0.09). Both
ibuprofen and diclofenac treatments were associated with a
significantly (Po0.05) greater proportion of patients with
systolic BP elevations 420 mmHg and above 140 mmHg as
compared with celecoxib (treatment differences 1.6–2.0%).
No treatment differences were observed for diastolic BP
(Table 3). Withdrawals from study treatment owing to
hypertension-related adverse events were uncommon and
Table 1 | Baseline characteristics and exposure to treatment
Celecoxib
400 mg b.i.d.
(N=3987)
Diclofenac
75 mg b.i.d.
(N=1996)
Ibuprofen
800 mg t.i.d.
(N=1985)
Exposure to treatment
Median (days) 273 257 186
Total (patient-years) 2320 1081 1122
Age
Mean (years) 60.6 60.1 59.5
65–74 years (%) 26.9 26.4 25.5
X75 years (%) 12.2 11.8 10.9
Female (%) 68.5 67.4 70.8
History (%)
Hypertension 39.0 38.9 38.1
Diabetes 8.8 7.5 8.1
Blood pressure (mmHg)
Systolic 132.7 133.0 132.6
Diastolic 79.4 79.5 79.9
Creatinine
Serum level (mg/dl) 0.79 0.79 0.77
Clearance (ml/mina) 112.2 112.0 116.4
b.i.d., twice a day; t.i.d., three times a day.
aEstimated by the Cockcroft–Gault formula.
Table 2 | Summary of antihypertensive and diuretic
medication use at baseline
Drug
N (% of patients)
Celecoxib
400 mg b.i.d.
(N=3987)
Diclofenac
75 mg b.i.d.
(N=1996)
Ibuprofen
800 mg t.i.d.
(N=1985)
Any antihypertensive or
diuretic medication
1688 (42.3) 859 (43.0) 845 (42.6)
ACE inhibitors 528 (13.2) 266 (13.3) 240 (12.1)
Alpha adrenergic agonists 209 (5.2) 95 (4.8) 87 (4.4)
Angiotensin II receptor
antagonists
128 (3.2) 64 (3.2) 70 (3.5)
Beta-blockers 473 (11.9) 238 (11.9) 260 (13.1)
Calcium channel blockers 511 (12.8) 283 (14.2) 274 (13.8)
Diuretics 764 (19.2) 412 (20.6) 393 (19.8)
ACE, Angiotensin-converting enzyme; b.i.d., twice a day; t.i.d., three times a day.
Table 3 | Blood pressure effects of celecoxib vs diclofenac or ibuprofen
Event
Celecoxib 400 mg
b.i.d. (N=3987)
Diclofenac 75 mg
b.i.d. (N=1996)
Ibuprofen 800 mg
t.i.d. (N=1985)
Any hypertension adverse event (% of patients)a 2.7 2.6 4.2*
New-onset hypertension (% of patients) 2.0 2.0 3.1*
Aggravated hypertension (% of patients) 0.8 0.6 1.2
Withdrawals for hypertension-related adverse events (% of patients)a 0.3 0.2 0.3
Mean change in blood pressure (mmHg)
Systolic –0.6 –0.8 0.3
Diastolic –0.7 –1.1 –0.6
Increases in blood pressure (% of patients)b
Systolic 420 mmHg from baseline and absolute value 4140 mmHg 5.0 6.6* 7.0*
Diastolic 415 mmHg from baseline and absolute value 490 mmHg 1.9 1.2 2.2
b.i.d., twice a day; t.i.d., three times a day.
aNew-onset or aggravated.
bObserved at final clinic visit.
*Po0.05 versus celecoxib by Fisher exact test.
Kidney International (2006) 70, 1495–1502 1497
A Whelton et al.: Cardiorenal safety of celecoxib o r i g i n a l a r t i c l e
occurred with similar frequency among the three treatment
groups (Table 3).
The initiation of new antihypertensive and diuretic
therapy was significantly higher with ibuprofen treatment
as compared with celecoxib treatment and specifically for
initiation of angiotensin II receptor antagonists, calcium
channel blockers, and diuretic therapies (Table 4). No
significant differences were observed in the use of anti-
hypertensives between the celecoxib and diclofenac treatment
groups. Upward adjustments of antihypertensive or diuretic
therapies already being administered to patients in order to
maintain BP control were not considered in this analysis. Of
the patients summarized in Table 4, 59% (229/391) celecoxib-
treated patients, 58% (107/184) diclofenac-treated patients,
and 56% (133/238) ibuprofen-treated patients were already
receiving antihypertensive or diuretic therapy at baseline and,
therefore, were being initiated to a second agent concurrently
or being switched from one treatment to another. For the
remaining approximately 40% of patients in this cohort
across the treatment groups, the initiation of antihyper-
tensive or diuretic therapy occurred in the absence of any
baseline treatment.
Fluid retention
Celecoxib treatment was associated with a similar incidence
of investigator-reported edema (including either peripheral
or generalized edema) compared with diclofenac and a
significantly lower incidence compared with ibuprofen
(Po0.05) (Table 5). This higher incidence of edema in
patients taking ibuprofen paralleled a significantly greater use
of new diuretic use compared with celecoxib-treated patients
(Po0.05) (Table 4). No significant differences were noted in
diuretic use between patients assigned to celecoxib and
diclofenac.
Adverse events of congestive heart failure were uncom-
monly reported by investigators (approximately one-tenth
the rate of overall edema) and no significant differences
were detected between treatments (Table 5). In addition, no
significant treatment differences were observed with respect
to body weight gains of X3%.
Withdrawals from study treatment owing to either edema
or congestive heart failure were uncommon overall and no
significant treatment-related differences were detected.
Renal function
Renal function of enrolled patients was normal, as reflected
by baseline serum creatinine levels or estimated creatinine
clearance (Table 1). Nearly all patients (499%) had a serum
creatinine p1.5 mg/dl, which reflects normal renal function
required per protocol.
Renal function, as reflected by serum creatinine or
estimated creatinine clearance, decreased significantly in
patients assigned to diclofenac compared with those receiving
celecoxib (Po0.05) (Table 6). A nonsignificant trend towards
decreased renal function was observed in patients treated
with ibuprofen relative to those patients receiving celecoxib
(Table 6).
Clinically important renal dysfunction, defined as (1)
increases in serum creatinine 40.5 mg/dl relative to baseline
or serum creatinine 41.5 mg/dl at any post-baseline assess-
ment or (2) a decrease in estimated creatinine clearance
X30% relative to baseline are provided in Figure 2. For the
entire treatment cohort, one significant treatment difference
was detected: the incidence ofX30% reductions in estimated
creatinine clearance from baseline was significantly lower in
patients treated with celecoxib as compared with diclofenac.
An evaluation of the time course of these changes (data not
shown) revealed that the highest frequency occurred early
after initiation of treatment (week 4 and 13 clinic visits) and
declined thereafter, rather than a progressively increasing risk
Table 4 | Initiation of antihypertensive and diuretic
medications
Drug
N (% of patients)
Celecoxib
400 mg b.i.d.
(N=3987)
Diclofenac
75 mg b.i.d.
(N=1996)
Ibuprofen
800 mg t.i.d.
(N=1985)
Any new antihypertensive
or diuretic medicationa
391 (9.8) 184 (9.2) 238 (12.0)*
ACE inhibitors 108 (2.7) 63 (3.2) 62 (3.1)
Alpha adrenergic agonists 45 (1.1) 15 (0.8) 12 (0.6)
Angiotensin II receptor
antagonists
34 (0.9) 17 (0.9) 39 (2.0)**
Beta-blockers 74 (1.9) 36 (1.8) 38 (1.9)
Calcium channel blockers 79 (2.0) 34 (1.7) 62 (3.1)**
Diuretics 153 (3.8) 84 (4.2) 103 (5.2)*
ACE, Angiotensin-converting enzyme; b.i.d., twice a day; t.i.d., three times a day.
aIf a patient received more than one antihypertensive/diuretic medication, that
patient is counted once in the overall incidence for any drug.
*Po0.05 versus celecoxib by Fisher exact test.
**Po0.01 versus celecoxib by Fisher exact test.
Table 5 | Fluid retention effects of celecoxib versus diclofenac or ibuprofen
Celecoxib 400 mg
b.i.d. (N=3987)
Diclofenac 75 mg
b.i.d. (N=1996)
Ibuprofen 800 mg
t.i.d. (N=1985)
Any edema-related adverse event (% of patients)a 4.1 4.1 6.2*
Withdrawals for edema-related adverse events (% of patients)a 0.7 0.4 1.0
Congestive heart failure (% of patients) 0.3 0.2 0.5
Withdrawals due to congestive heart failure (% of patients) 0.1 o0.1 0.3
Increase in body weight of X3% (% of patients) 20.7 17.6 21.1
b.i.d., twice a day; t.i.d., three times a day.
aIncludes investigator reports of edema, generalized edema or peripheral edema.
*Po0.05 versus celecoxib by Fisher exact test.
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as a function of duration of treatment in all three treatment
groups. It should be noted, however, that a substantial
proportion of patients exhibited these changes 6 months or
longer after treatment was initiated, suggesting that the
hazard, although perhaps diminishing with time, does
continue throughout the therapy period. Increases in serum
creatinine of 41.0 mg/dl were uncommon, occurring in
nine celecoxib-treated patients (0.2%), two diclofenac-
treated patients (0.1%), and two patients taking ibuprofen
(0.2%). These treatment differences were not significantly
different.
For those patients characterized by mild prerenal azotemia
at baseline (serum blood urea nitrogen 420 mg/dl) but
relatively normal renal function (Table 7), the incidence of
clinically important changes in renal function was at least
twofold lower (Po0.05) in patients receiving celecoxib
compared with either diclofenac- or ibuprofen-treated
patients (Figure 2). Treatment differences in mean serum
creatinine and estimated creatinine clearance were also
observed in this cohort (Table 7). No differences were
observed between treatment groups for patients without
baseline azotemia (i.e., with blood urea nitrogenp20 mg/dl)
(Figure 2).
Patients with normal serum creatinine/prerenal azotemia
at baseline were significantly more likely to withdraw from
the study owing to an adverse event if their creatinine level
increased to 41.5 mg/dl on treatment versus the overall
cohort (relative risk, 2.0; Po0.05). When expressed as a
percentage of the patients with normal serum creatinine/
prerenal azotemia at baseline, the withdrawal rate in patients
treated with celecoxib (1.5%) was significantly lower
Table 6 | Renal effects of celecoxib versus diclofenac or ibuprofen
Celecoxib 400 mg
b.i.d. (N=3987)
Diclofenac 75 mg
b.i.d. (N=1996)
Ibuprofen 800 mg
t.i.d. (N=1985)
Mean change in serum creatinine (mg/dl) (n=3692) 0.00970.002 (n=1850) 0.02770.004* (n=1786) 0.01770.004
Mean change in estimated
creatinine clearance (ml/min)
(n=3668) 0.0870.37 (n=1846) 2.8270.51* (n=1775) 0.9670.56
b.i.d., twice a day; t.i.d., three times a day.
*Po0.05 versus celecoxib by analysis of covariance or by Fisher exact test.
Figure 2 | The incidence of increases in serum creatinine
40.5 mg/dl relative to baseline or serum creatinine 41.5 mg/dl
at any post-baseline assessment (top panel) or decreases in
estimated creatinine clearance X30% relative to baseline
(bottom panel) are shown for all patients, non-azotemic patients,
and azotemic patients who had both a baseline and a treatment
determination at their final clinic visit. *Po0.05 versus celecoxib
by Fisher exact test and **Po0.01 versus celecoxib by Fisher
exact test.
Table 7 | Renal function in patients with prerenal azotemia
at baseline (BUN 420 mg/dl)
Celecoxib
400 mg b.i.d.
(N=592)
Diclofenac
75 mg b.i.d.
(N=300)
Ibuprofen
800 mg t.i.d.
(N=260)
Baseline serum
creatinine (mg/dl)
0.93 0.94 0.93
Estimated baseline
creatinine clearance
(ml/min)
91.1 91.3 94.3
Mean change in
serum creatinine
(mg/dl)
0.00370.007 0.04970.012* 0.03370.015*
Mean change in
estimated creatinine
clearance (ml/min)
1.2770.69 1.6571.03* 1.3471.28
b.i.d., twice a day; BUN, blood urea nitrogen; t.i.d., three times a day.
*Po0.05 by analysis of covariance or by Fisher exact test.
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compared with those receiving diclofenac (3.7%; Po0.05)
and ibuprofen (4.2%; Po0.05).
Electrolyte and acid base
Changes in mean serum levels of sodium, potassium,
chloride, and bicarbonate were minimal between treatment
groups and were not of clinical significance (data not shown).
Serious cardiorenal-related adverse events
The incidence of serious cardiorenal-related adverse events
during treatment with celecoxib, ibuprofen, or diclofenac was
low. The study investigators reported one case of uremia in
an ibuprofen-treated patient. Two cases of hyponatremia
were reported in patients treated with celecoxib and one case
was reported in a patient taking ibuprofen. No cases of
serious adverse events related to nephrotic syndrome,
interstitial nephritis, or papillary necrosis were observed.
DISCUSSION
The large cardiorenal database from the CLASS trial has
provided the opportunity to observe and compare the natural
history of the onset and clinical management of cardiorenal-
related adverse events that evolve when exposing a typical
adult arthritic population to chronic treatment with a
nonselective NSAID or supratherapeutic doses of the COXIB,
celecoxib. Thus, the study provides a new and important
clinical resource of therapeutic cardiorenal safety informa-
tion. The data have permitted the description of a clinical
paradigm wherein certain key patient characteristics may
provide additional predictive clinical information with
respect to future drug-specific susceptibility to impairment
of cardiorenal function.
The present analysis supports the hypothesis that RA and
OA patients receiving celecoxib 400 mg b.i.d. (two- to
fourfold greater than the maximum effective doses for RA
and OA) have an overall reduced risk of cardiorenal-related
adverse events compared with standard therapeutic doses of
the nonselective NSAIDs, diclofenac 75 mg b.i.d. and
ibuprofen 800 mg three times a day. In particular, celecoxib
treatment was superior to the nonselective NSAIDs with
respect to renal function in patients with prerenal compro-
mise. Some important differences were observed in the
cardiorenal safety profiles of celecoxib versus nonselective
NSAIDs and between the respective nonselective NSAIDs.
Compared with celecoxib, the incidence of adverse events
related to hypertension and edema were significantly higher
with ibuprofen (but not diclofenac), and decline in renal
function was more apparent with diclofenac than with
ibuprofen. These data provide a greater understanding of the
relative effects of these agents on cardiorenal function and
homeostasis.
The increased incidence of hypertension in patients taking
ibuprofen versus celecoxib appeared to be largely a function
of effects on systolic, rather than diastolic, BP. Both
diclofenac and ibuprofen were associated with significantly
higher incidences of clinically meaningful elevations in
systolic BP versus celecoxib. The importance of systolic BP
has been highlighted in the Systolic Hypertension in Elderly
Program trial,23 the Systolic hypertension in Europe trial24
and the Antihypertensive and Lipid-Lowering treatment to
prevent Heart Attack Trial (ALLHAT).25 These studies
showed that elevated systolic BP is associated with heart
failure, stroke, myocardial infarction, and death. Evidence
now indicates that destabilization of BP in treated hyper-
tensive patients, by rofecoxib, is a significant risk marker for
the development of acute myocardial infarction and stroke
events.26 Much additional information with respect to the
latter issues, and the emergence that some NSAIDs may also
cause cardiotoxicity, is reviewed elsewhere.27
Long-term treatment with supratherapeutic doses of
celecoxib in the CLASS trial had little effect on BP levels in
these arthritis patients. This finding is supported by previous
studies demonstrating that celecoxib does not affect mean
systolic BP changes in hypertensive patients treated with
diuretics or antihypertensive agents.28–30 In contrast, many
NSAIDs and some COXIBs, such as rofecoxib, antagonize the
BP-lowering effects of certain antihypertensive agents, in
particular, angiotensin-converting enzyme inhibitors and
b-blockers.31–34
In the present analysis, celecoxib was superior to the
nonselective NSAIDs studied with respect to renal dysfunc-
tion. Diclofenac, more so than ibuprofen, appeared to cause a
significantly higher rate of decline in renal function than
celecoxib. This may suggest a disproportionate effect of
diclofenac on renal perfusion. Importantly, in patients with
prerenal azotemia (but normal creatinine) at baseline,
celecoxib was associated with a lower rate of deterioration
of renal function compared with both diclofenac and
ibuprofen. However, as some renal dysfunction was evident
in the celecoxib treatment group, caution should still be used
when treating patients at risk of adverse renal events. Changes
in electrolyte levels were small and were not of clinical
relevance.
Our results highlight that there are differential cardiorenal
effects associated with celecoxib versus nonselective NSAIDs,
and between the two NSAIDs, diclofenac and ibuprofen.
Previous studies have also shown that cardiorenal safety
profiles are not consistent across the class of COXIBs. For
example, rofecoxib treatment is associated with dose-
dependent increases in hypertension and edema.28,35 In two
recent, 6-week, randomized, double-blind trials of OA
patients taking antihypertensive agents, the study partici-
pants taking celecoxib 200 mg daily were less likely to
experience renal adverse events than the group receiving
rofecoxib 25 mg daily.28 The differing renal safety profiles
across the classes of nonselective NSAIDs and COXIBs
suggest that some of the renal effects of the latter may be
‘molecule-specific’, rather than as a result of a ‘class effect’ of
COX-2 inhibition.27
Our results suggest that the clinical management of
arthritis patients may be impacted by the agent selected to
treat their pain and by patients’ underlying health status with
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regard to cardiorenal side effects. Our results indicate that
cardiorenal side effects are relatively common with NSAID
treatment and require careful medical monitoring of patients
together with other safety-related parameters (e.g., hepato-
toxicity associated with some NSAIDs such as diclofenac).
Anti-inflammatory drug-induced effects on BP or renal
function should be cautiously monitored clinically during the
use of such drugs. These adverse renal events may be
selectively reduced or minimized by the selection of an anti-
inflammatory drug, such as celecoxib, that appears to have
the least detrimental effects upon renal function, as
demonstrated in our study.
The present analysis has some potential limitations. Many
OA and RA patients are elderly and have significant
comorbidity, including cardiovascular disease, hypertension,
and abnormal renal function. However, the CLASS trial did
not include patients with abnormal renal function at
baseline, and results cannot be applied to these patients.
Thus, further work is needed to study the renal safety profile
of nonspecific NSAIDs and COXIBs in patients with
abnormal renal function. Another limitation in the present
analysis is that patients in this study were not stratified by
baseline body weight, which may impact significantly on
baseline creatinine levels.
In conclusion, in a large adult arthritic population,
supratherapeutic doses of celecoxib (400 mg b.i.d.) were
associated with a reduced incidence of abnormal cardiorenal
function, as assessed by investigator reports of hypertension,
edema formation, or congestive heart failure, clinical
measures of glomerular filtration, and various measures of
destabilization of BP control, compared with standard doses
of diclofenac 75 mg b.i.d. or ibuprofen 800 mg three times a
day. In patients with mildly compromised renal function at
baseline, celecoxib was associated with a lower rate of
deterioration of renal function compared with both diclo-
fenac and ibuprofen. These data suggest that celecoxib may
frequently be a more suitable treatment of chronic pain and
inflammation than nonselective NSAIDs in patients with
compromised renal function.
MATERIALS AND METHODS
Study population and protocol
Details of the CLASS study population and protocol have been
published previously.22,36 In brief, outpatientsX18 years of age were
eligible to participate in the study if, upon screening, they were
diagnosed with RA or OA evident for X3 months that required
continuous treatment with an NSAID for the duration of the trial.
Other inclusion and exclusion criteria were derived from the
product label in order to mirror clinical practice.
Patients with significant renal disease that was considered by the
investigator to be clinically significant were excluded from the
CLASS population. The upper limit for serum creatinine was
1.5 mg/dl, which reflected the upper limit for normal renal function.
Clinically important renal dysfunction was defined in the CLASS
protocol as an increase in serum creatinine 40.5 mg/dl from
baseline or a serum creatinine value above 1.5 mg/dl during double-
blind treatment.
The CLASS trial was a randomized, double-blind, parallel-group
study based on two protocols, the results of which were
prospectively combined for analysis. The two separate protocols
represented a comparison between celecoxib and a nonselective
NSAID, ibuprofen or diclofenac. The study involved 386 centers in
the United States and Canada from December 1998 to January 2000.
Patients were randomized 1:1 to receive celecoxib 400 mg and a
nonselective NSAID, ibuprofen 800 mg three times a day or
diclofenac 75 mg b.i.d.
The concomitant use of stable doses of aspirin up to 325 mg daily
was permitted during the trial. Patients who began taking aspirin
during the course of the trial were not removed from the study and
were included in all analyses. After a baseline visit, follow-up clinic
visits took place at weeks 4, 13, 26, and every 13 weeks thereafter,
following the initial dose of study medication until study
termination. Some patients took study medication for up to 15
months. All patients were provided an opportunity to complete a
minimum of 6 months of treatment (Table 1).
Clinical assessments
Adverse event data were collected by investigators at each clinic
visit using the following question: ‘Since your last visit, have
you experienced or do you currently have any symptoms that
are not associated with your arthritis?’ All positive responses
were recorded regardless of severity or relationship to study drug.
Adverse events were judged to be ‘serious’ if they resulted
in a fatality or hospitalization, or if the principal investigator
felt that the event was life threatening or otherwise medically
significant. Withdrawal rates owing to each adverse event were also
recorded.
In the present analysis, all study data generated over a median
exposure time of 9 months are presented for investigator-reported
adverse events. These adverse events included new-onset or
aggravated pre-existing hypertension, peripheral and generalized
edema, and congestive heart failure. In addition, we analyzed the
incidence of elevations in BP using the criteria for systolic BP of a
420 mmHg increase from baseline and absolute value 4140 mmHg
and for diastolic BP a 415 mmHg increase from baseline and
absolute value 490 mmHg, consistent with a previous study.29 The
introduction of new antihypertensive and diuretic medications was
analyzed to assess the clinical relevance of observed effects on BP
and edema. Body weight changes of at leastX3% increase were also
evaluated. The incidence of serum creatinine elevations was
determined using the criteria 40.5 mg/dl increase over baseline or
any value 41.5 mg/dl during treatment. The incidence of reductions
in estimated creatinine clearance (as calculated by the Cockcroft–-
Gault formula: 140agewt/[serum creatinine] 72) of X30%
from baseline during treatment was analyzed as well. The latter two
analyses were also performed as a contingency analysis based on the
presence of mild prerenal azotemia, defined as a baseline blood urea
nitrogen level of 420 mg/dl.
Statistical analysis
Statistical analyses were conducted on the ITT population, which
was defined a priori in the original CLASS protocol as all patients
who received at least one dose of assigned study medication.
Baseline demographic characteristics and risk factors were compared
using two-way analysis of variance or Pearson’s w2. Incidences of
treatment-emergent renovascular adverse events or clinical labora-
tory changes during the entire study were tabulated and compared
using the Fisher exact test. Analyses of BP, serum creatinine and
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creatinine clearance were performed on changes from baseline to the
final clinic visit for each patient.
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